1. Home
  2. INDO vs EQ Comparison

INDO vs EQ Comparison

Compare INDO & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indonesia Energy Corporation Limited

INDO

Indonesia Energy Corporation Limited

HOLD

Current Price

$3.70

Market Cap

68.3M

Sector

Energy

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.61

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDO
EQ
Founded
2018
2017
Country
Indonesia
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.3M
64.5M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
INDO
EQ
Price
$3.70
$1.61
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
1.6M
502.7K
Earning Date
09-30-2025
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,293,625.00
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.10
$0.27
52 Week High
$7.95
$2.35

Technical Indicators

Market Signals
Indicator
INDO
EQ
Relative Strength Index (RSI) 48.08 66.20
Support Level $3.25 $1.41
Resistance Level $4.06 $1.61
Average True Range (ATR) 0.47 0.12
MACD -0.08 0.02
Stochastic Oscillator 20.10 83.81

Price Performance

Historical Comparison
INDO
EQ

About INDO Indonesia Energy Corporation Limited

Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. The company is an independent energy company engaged in the oil and gas business and holds two oil and gas assets through its subsidiaries in Indonesia: The Kruh Block and the Citarum Block. It has also identified a potential third exploration block known as the Rangkas area. . Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: